Selective COX-2 inhibitors: Potentials and limits;Inhibiteurs selectifs de la cyclooxygenase de type 2 (COX-2): Interets et limites

Therapie

Volumn 54, Issue 4, 1999, Pages 433-445

  Pairet, M ^a   Netter, P ^b   Jouzeau, J Y ^c   Bouvenot, G ^c   Berdeaux, A ^c   Bertin, P ^c   Bonnet, J ^c   Bourin, M ^c   Caussade, F ^c   Charpigny, G ^c   Chazelle, F ^c   Daouphars, M ^c   David, N ^c   Drici, M D ^c   Dropsy, R ^c   Guerin V ^c   Joubert, J M ^c   Larousse, C ^c   Neant F ^c   Picot, D ^c   Riendeau, D ^c   Sassard, J ^c   Terlain, B ^c   more..

^a Boehinger Ingelheim Pharma KG Dept of Pulmonary Research   (Germany)

^b UNIVERSITÉ DE LORRAINE   (France)

^c NONE

Author keywords

COX 1; COX 2; Cycloxoygenase (COX); Non steroidal anti inflammatory drugs (NSAIDs); Possible new indications; Side effects

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2; ISOENZYME; LACTONE; MEMBRANE LIPID; MEMBRANE PROTEIN; PHOSPHOLIPID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE; VALINE;

CONFERENCE PAPER; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; PRIORITY JOURNAL; ALZHEIMER DISEASE; ANIMAL; BINDING SITE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG EFFECT; ENZYME INDUCTION; ENZYME SPECIFICITY; HUMAN; INTESTINE MUCOSA; KIDNEY; METABOLISM; MOUSE; PEPTIC ULCER; REPRODUCTION; REVIEW; SAFETY; STOMACH MUCOSA;

ALZHEIMER DISEASE; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ARACHIDONIC ACIDS; BINDING SITES; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME INDUCTION; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; ISOENZYMES; KIDNEY; LACTONES; MEMBRANE LIPIDS; MEMBRANE PROTEINS; MICE; PEPTIC ULCER; PHOSPHOLIPIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; REPRODUCTION; SAFETY; SUBSTRATE SPECIFICITY; SULFONAMIDES; SULFONES; VALINE;

EID: 0033155163     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (141)

1. CSM. (Commitee on the Security of Medicines) Update. Non-steroidal antiinflammatory drugs and serious gastrointestinal adverse reactions. BMJ 1986; 292: 1190-1191.
2. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 (suppl 28): 6-10.
3. Griffin MR, Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (suppl 3A): 23S-29S.
4. Garcia Rodriguez LA, Jick H. Risks of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-772.
5. Langmann MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078.
6. Henry DH, Lim LL-Y, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566.
7. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (New Biol.) 1971; 231: 232-235.
8. Fu JY, Masferrer JL, Seibert K et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-16740.
9. Vane JR. Towards a better aspirin. Nature 1994; 367: 215-216.
10. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 1996; 10: 1-15.
11. Berenbaum F. Les cyclooxygénases et leurs inhibiteurs. Rev Rhum 1998; 65: 701-708.
12. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-249.
13. Kurumbail R, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-648.
14. Luong C, Miller A, Barnett J et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 1996; 3: 927-933.
15. Jouzeau JY, Terlain B, Abid A et al. Cyclo-oxygenases isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 53: 563-582.
16. Dubois R, Abramson S, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
17. Pairet M, van Ryn J, Distel M. Overview of COX-2 in inflammation: from the biology to the clinic. In: Willoughby D, Tomlinson A, eds. Progress in Inflammation: Inducible Enzymes in the Inflammatory Response. Basel: Birkhäuser, 1998: 1-30.
18. Sano H, Hla T, Maier et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and in rats with adjuvant and streptococcal cell wall arthritis. J. Clin Invest 1992; 89: 97-108.
19. Crofford LJ. Cyclooxygenase-1 and -2 in synovial tissues of arthritic patients. In: Vane JR, Botting RM, eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 41-48.
20. Siegle I, Klein R, Backman JT et al. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum. 1998; 41: 122-129.
21. Eberhardt CE, Coffey RJ, Radhika A et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
22. Slater DM, Berger L, Newton R et al. Changes in expression of types 1 and 2 cyclooxygenase in human fetal membranes at term. Am J Obstet Gynecol 1995; 14: 237-244.
23. Bennett P, Sawdy R, Slater D. The role of cyclooxygenase-2 in reproduction. In: Vane JR, Botting RM, eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 171-183.
24. Oka A, Takashima S. Induction of cyclooxygenase 2 in brains of patients with Down's syndrome and dementia of the Alzheimer's type: specific localization in affected neurones and axons. Neuroreport 1997; 8: 1161-1164.
25. O'Banion MK. Cyclooxygenase-2 in Alzheimer's disease. In: Vane JR, Botting RM, eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 185-192.
26. Kaufmann WE, Worley PF, Pegg J et al. COX-2, a synaptically-induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-2321.
27. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-160.
28. Harris RC, McKanna, JA, Akai Y et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-2510.
29. Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cydooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998; 47 (Suppl 2): S93-S101.
30. Copeland RA, Williams JM, Giannaras J et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci. USA 1994; 91: 11202-11206.
31. Ouellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995; 306: 247-251.
32. Riendeau D, Percival MD, Boyce S et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997; 121: 105-117.
33. Riendeau D, Charleson S, Cromlish et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelets assays. Can J Physiol Pharmacol 1997; 75: 1088-1095.
34. Patrignani P, Panara MR, Greco A et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-1712.
35. Brideau C, Kargman, Liu S et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74.
36. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 1997; 45: 44-49.
37. Cullen L, Kelly L, Connor SO et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 1998; 287: 578-582.
38. Panara MR, Padovano R, Sciulli MG et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin Pharmacol Ther 1998; 63: 672-681.
39. Steinhaeuslin F, Munajo A, Buclin T et al. Renal effects of nimesulide in furosemide-treated subjects. Drugs 1993; 46 (suppl 1): 257-262.
40. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998; 41: 1591-1602.
41. Mengle-Gaw L, Hubbard R, Karim A et al. A study of the platelet effects of SC58635, a novel COX-2 selective inhibitor (abstract). Arthritis Rheum 1997; 40 (suppl 9): A 374.
42. Ehrich E, Dallob A, van Hecken A et al. Demonstration of selective COX-2 inhibition by MK-966 in humans (abstract). Arthritis Rheum 1996; 39 (suppl 9): A 328.
43. Depré M, Ehrich E, DeLepeleire I et al. Demonstration of specific COX-2 inhibition by MK-966 (VIOXX™) in humans with supratherapeutic doses (abstract). Rheum Eur 1998; 27 (suppl 2): 118 (A196).
44. Ehrich EW, Dallob A, Delepeleire I et al. Characterization of Rofecoxib as a cyclooxygenase 2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1998 (sous presse).
45. McAdam BF, Catella-Lawson F, Mardini IA et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-S: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 1: 272-277.
46. Gierse JK, McDonald JJ, Hauser SD et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and 2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271: 15810-15814.
47. Wong E, Bayly C, Waterman HL et al. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2 selective inhibitors by a double His513→Arg and Ile523→Val mutation. J Biol Chem 1997; 272: 9280-9286.
48. Browner MF. The structure of human COX-2 and selective inhibitors. In: Vane JR, Botting J eds. Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential London: Kluwer Academic Publishers and William Harvey Press, 1998: 19-26.
49. Picot D. The three-dimensional structure of cyclooxygenases. In: Szczeklick A, Gryglewski RJ, Vane JR, eds. Eicosanoids, Aspirin and Asthma. New York: Marcel Dekker, 1998: 161-186.
50. So OY, Scarafia LE, Mak AY et al. The dynamics of prostaglandin H synthases. Studies with prostaglandin H synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J Biol Chem 1998; 273: 5801-5807.
51. Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-409.
52. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase gene disruption can cause severe renal pathology in the mouse. Cell 1995; 83: 473-482.
53. Wallace JL, Bak A, McKnight W et al. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115: 101-109.
54. Futaki N, Yoshikawa K, Hamasaka Y et al. NS-398, a novel non-steroid anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-110.
55. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
56. Seibert K, Zhang Y, Leahy et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.
57. Chan CC, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 274: 1531-1537.
58. Anderson GD, Hauser SC, McGarity KL et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-2679.
59. Smith CJ, Zhang Y, Koboldt C et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998; 95: 13313-13318.
60. van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Exp Opin Invest Drugs 1997; 6: 609-614.
61. Ehrich E, Schnitzer T, Weaver et al. Treatment with MK-0966 (VIOXX™), a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee and hip, that was sustained over six months (abstract). Rheum Eur 1998; 27 (suppl. 2): 119 (A198).
62. Hay C, de Belleroche J. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport 1997; 8: 1249-1251.
63. Matsushita M, Masaki M, Yagi Y et al. Pharmacological profile of JTE-522, a novel prostaglandin H synthase inhibitor, in rats. Inflamm Res 1997; 46: 461-466.
64. Zhang Y, Schaffer A, Portanova J et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997; 283: 1069-1075.
65. Ding DM, Isakson PC, Yaksh TL. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol Exp Ther 1998; 285: 1031-1038.
66. Hay C, Trevethick MA, Wheeldon A et al. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. Neuroscience 1997; 78: 843-850.
67. Ding DM, Konin GP, Isakson PC, Yaksh TL. Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release. Eur J Pharmacol 1997; 331: 155-160.
68. Euchenhofer C, Mailhoefner C, Brune K et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248: 25-28.
69. Kusuhara H, Fukunari A, Matsuyuki H, Okumoto T. Principal involvement of cyclooxygenase-1-derived prostaglandins in the c-fos expression of the rat hind brain following visceral stimulation with acetic acid. Mol Brain Res 1997; 52: 151-156.
70. Geis GS, Hubbard R, Callison D et al. Safety and efficacy of Celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis (abstract). Arthritis Rheum 1998; 41 (suppl. 9): S 364 (A 1990).
71. Hubbard R, Geis GS, Woods E et al. Efficacy, tolerability, and safety of Celecoxib, a specific COX-2 inhibitor, in osteoarthritis (abstract). Arthritis Rheum 1998; 41 (suppl 9): S196 (A982).
72. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. JRheumatol 1997; 24 (suppl 49): 20-24.
73. Mehlisch DR, Mills S, Sandler M et al. Ex vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966 (abstract). Clin Pharmacol Ther 1998; 63 (2): 139.
74. Cannon G, Caldwell J, Holt P et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week controlled clinical trial (abstract). Arthritis Rheum 1998; 41 (suppl. 9): S196 (A983).
75. Lanza FL, Rack MF, Callison DA et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor (abstract). Gastroenterology 1997; 112: A194.
76. Lanza FL, Simon T, Quan H et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.I.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. (abstract). Gastroenterology 1997; 112: A194.
77. Le Loet X, Kahan A, Tebib J et al. Tolérance gastrique et duodénale endoscopique du célécoxib, inhibiteur spécifique de la COX-2, versus diclofénac dans la polyarthrite rhumatoide, en phase III (abstract). Rev Rhum 1998; 11: 816 (B134).
78. Hawkey C, Kahan A, Steinbrück et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-945.
79. Dequeker J, Hawkey, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-951.
80. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by specific antagonists delays healing in mice. Gastroenterology 1997; 112: 387-397.
81. Shigeta JC, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998; 286: 1383-1390.
82. 82a. Zimmermann KC, Sarbia M, Schrör K et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Molec Pharmacol 1998; 54: 536-540.
83. 82b. Laine L, Hawkey C, Harper C et al. Effect of the COX-2 specific inhibitor (C-255) rofecoxil on diet formation: a double-blind comparison with ibuprofein. Gastroenterology (Abstract) 1999; 116: A229.
84. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(suppl 1): S56-S62.
85. Wen SF. Nephrotoxicities of nonsteroidal anti-inflammatory drugs. J Formos Med Assoc 1997; 96 (3): 157-171.
86. Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmacol 1995; 35: 454-463.
87. Stichtenoth DO, Froelich JC. Avoidance of renal side effects of non-steroidal anti-inflammatory drugs: value of selective cyclooxagenase-2 inhibition. In: Vane JR, Botting RM eds. Clinical Significance and Potential of Selective COX-2 Inhibitors. London: William Harvey Press, 1998: 99-108.
88. Venturini CM, Isakson P, Needleman P. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclooxygenase isoforms. Curr Opin Nephrol Hypertension 1998; 7: 79-82.
89. Kömhoff M, Gröne HJ, Klein T et al. Localization of cyclooxygenase-1 and 2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460-F468.
90. Hartner A, Goppelt-Struebe M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 1997; 31: 201-205.
91. Tomasoni S, Noris M, Zapella S et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9: 1202-1212.
92. De Forrest JM, Davis JO, Freeman RH et al. Effects of indomethacin and meclofenamate on renin release and renal hemodynamic function during chronic sodium depletion in conscious dogs. Circulation Res 1980; 47: 99-107.
93. Brooks DP, Adams J, DePalma PD et al. The selective cyclooxygenase-2 inhibitor, celecoxib, but not 6-MNA, affects renal hemodynamic and renal function in the dog. J Rheumatol (abstract) 1998; 25 (suppl 52): M64.
94. Hedin L, Gaddy-Kurten D, Kurten R et al. Prostaglandin endoperoxide synthase in rat ovarian follicles: content, cellular distribution and evidence for hormonal induction preceding ovulation. Endocrinology 1987; 121: 722-731.
95. Sirois J, Richard JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992; 267: 6382-6388.
96. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91: 187-208.
97. Murdoch WJ. Disruption of cellular associations within the granulosa compartment of periovulatory ovine follicles: relationship to maturation of the oocyte and regulation by prostaglandins. Cell Tissue Res 1988; 252: 459-462.
98. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16: 107-122.
99. Charpigny G, Reinaud P, Tamby JP et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in ovine endometrium in vivo. Endocrinology 1997; 138: 2163-2171.
100. Wu WX, Ma XH, Zhang Q et al. Regulation of prostaglandin endoperoxide H synthase 1 and 2 by estradiol and progesterone in nonpregnant ovine myometrium and endometrium in vivo. Endocrinology 1997; 138: 4005-4012.
101. Han SW, Lei ZM, Rao CV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996: 137: 1791-1797.
102. Gibb W, Sun M. Localization of prostaglandin synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996; 150: 497-503.
103. Wimsatt J, Nathanielsz PW, Sirois J. Induction of prostaglandin endoperoxide synthase isoform-2 in ovine cotyledonary tissues during late gestation. Endocrinology 1993; 133: 1068-1073.
104. Charpigny G, Reinaud P, Tamby JP et al. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period. Biol-Reprod 1997; 57: 1032-1040.
105. Szczeklik A, Sladek K, Dworski R et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154: 1608-1614.
106. Busse W. The role and contribution of leukotrienes in asthma. Ann Allerg Asthma Im 1998; 81: 17-29.
107. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-1600.
108. Spector SL. Leukotriene activity modulation in asthma. Drugs 1997; 54: 369-384.
109. Calhoun WJ. Summary of clinical trials with Zafirlukast. Am J Respir Crit Care Med 1998; 157: S238-S246.
110. Markham A, Faulds D. Montelukast (ADIS New Drug Profile). Drugs 1998; 56: 251-256.
111. Schuligoi R, Amann R, Prenn C, Peskar BA. Effects of the cyclooxygenase-2 inhibitor NS-398 on thromboxane and leukotriene synthesis in rat peritoneal cells. Inflamm Res 1998; 47: 227-230.
112. Dzau VJ, Packer M, Lilly LS et al. Prostaglandins in severe congestive heart failure. N Engl J Med 1984; 321: 347-352.
113. van den Ouweland FA, Gribnau FWJ, Meyboom RHB. Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age and Aging 1988; 17: 8-16.
114. van den Ouweland FA, Gribnau FWJ. Non-steroidal anti-inflammatory drugs as a prognostic factor in acute pulmonary oedema. Arch Intern Med 1987; 147: 178-179.
115. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-598.
116. Patrono C, Cipollone F, Renda G, Patrignani P. Cyclooxygenase enzymes in human vascular disease. In: Vane JR, Botting J eds. Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential London: Kluwer Academic Publishers and William Harvey Press, 1998: 73-78.
117. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Camp Neurol 1992; 322: 409-438.
118. Yamagata K, Andreasson, KI, Kaufmann WI et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-386.
119. Breder CD, DeWitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 196-315.
120. Sawdy R, Slater D, Fisk N et al. Use of a cyclooxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997; 350: 265-266.
121. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996; 25: 333-348.
122. Smalley WE, DuBois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
123. Little J. Aspirin and other nonsteroidal anti-inflammatory drugs and colorectal neoplasia. Int J Oncol 1994; 5: 1151-1162.
124. Kargman S, O'Neill G, Vickers P et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-4820.
125. Kutchera W, Jones DA, Matsunami N et al. Prostaglandin H synthase 2 is expressed abnormally in human colon. Cancer Res 1995; 55: 1556-1559.
126. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
127. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340.
128. Tsujii M, Kawano S, Tsujii S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
129. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87: 803-809.
130. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4569.
131. Kawanori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-412.
132. Sheng H, Shao J, Kirkland SC et al. Inhibition of human colon cancer growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-2259.
133. Shiff SL, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-1998.
134. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-686.
135. Breitner JCS. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-411.
136. O'Banion MK, Dusel JC, Chang JW et al. Interleukin-1β induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996; 66: 2532-2540.
137. Bauer MKA, Lieb K, Schulze-Osthoff K et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997; 243: 726-731.
138. 2. Proc Natl Acad Sci USA 1997; 94: 6500-6505.
139. Ohtsuki T, Kitagawa K, Yamagata K et al. Induction of cyclooxygenase-2 mRNA in gerbil hippocampal neurons after transient forebrain ischemia. Brain Res 1996; 736: 353-356.
140. Toco G, Freiremoar J, Schreiber SS et al. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain - implications for Alzheimer's disease. Exp Neurol 1997; 144: 339-349.
141. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclooxygenase-2 gene expression in neurones contributes to ischemic brain damage. J Neurosci 1997; 17: 46-55.